Potential of Lichen Secondary Metabolites against Plasmodium Liver Stage Parasites with FAS-II as the Potential Target
Authors:
- Alice TarunATAlice Tarun
- Mire ZlohMire Zloh
- Xujie ZhangXZXujie Zhang
- Hua XuHXHua Xu
- Peter J. TongePTPeter J. Tonge
- Scott G. FranzblauSFScott G. Franzblau
- Duc-Hung PhamDPDuc-Hung Pham
- Camila V. EsguerraCECamila V. Esguerra
- 19 June 2013
- journal article
- review article
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 76 (6) , 1064-1070
Abstract
Chemicals targeting the liver stage (LS) of the malaria parasite are useful for causal prophylaxis of malaria. In this study, four lichen metabolites, evernic acid (1), vulpic acid (2), psoromic acid (3), and (+)-usnic acid (4), were evaluated against LS parasites of Plasmodium berghei. Inhibition of P. falciparum blood stage (BS) parasites was also assessed to determine stage specificity. Compound 4 displayed the highest LS activity and stage specificity (LS IC50 value 2.3 μM, BS IC50 value 47.3 μM). The compounds 1–3 inhibited one or more enzymes (PfFabI, PfFabG, and PfFabZ) from the plasmodial fatty acid biosynthesis (FAS-II) pathway, a potential drug target for LS activity. To determine species specificity and to clarify the mechanism of reported antibacterial effects, 1–4 were also evaluated against FabI homologues and whole cells of various pathogens (S. aureus, E. coli, M. tuberculosis). Molecular modeling studies suggest that lichen acids act indirectly via binding to allosteric sites on the protein surface of the FAS-II enzymes. Potential toxicity of compounds was assessed in human hepatocyte and cancer cells (in vitro) as well as in a zebrafish model (in vivo). This study indicates the therapeutic and prophylactic potential of lichen metabolites as antibacterial and antiplasmodial agents.Keywords
This publication has 62 references indexed in Scilit:
- Novel Type II Fatty Acid Biosynthesis (FAS II) Inhibitors as Multistage Antimalarial AgentsChemMedChem, 2013
- Selective and Specific Inhibition of the Plasmodium falciparum Lysyl-tRNA Synthetase by the Fungal Secondary Metabolite CladosporinCell Host & Microbe, 2012
- Liver-stage malaria parasites vulnerable to diverse chemical scaffoldsProceedings of the National Academy of Sciences, 2012
- Characterization of Plasmodium Liver Stage Inhibition by HalofuginoneChemMedChem, 2012
- Drug Screen Targeted at Plasmodium Liver Stages Identifies a Potent Multistage Antimalarial DrugThe Journal of Infectious Diseases, 2012
- 2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infectionsBioorganic & Medicinal Chemistry, 2010
- Type II fatty acid synthesis is essential only for malaria parasite late liver stage developmentCellular Microbiology, 2009
- The Fatty Acid Biosynthesis Enzyme FabI Plays a Key Role in the Development of Liver-Stage Malarial ParasitesCell Host & Microbe, 2008
- A combined transcriptome and proteome survey of malaria parasite liver stagesProceedings of the National Academy of Sciences, 2008
- Studies ofToxoplasma gondiiandPlasmodium falciparumenoyl acyl carrier protein reductase and implications for the development of antiparasitic agentsActa Crystallographica Section D Structural Biology, 2007